目的 对比分析罗沙司他与重组人促红素(recombinant human erythropoietin，rhEPO)分别联合琥珀酸亚铁治疗维持性血液透析(maintenance hemodialysis，MHD)患者肾性贫血的临床疗效。方法 选择MHD肾性贫血患者120例，按照随机数字表法分为研究组和对照组，每组60例。对照组透析后使用rhEPO联合琥珀酸亚铁治疗，研究组透析后使用罗沙司他联合琥珀酸亚铁治疗。治疗前后，分别检测患者铁代谢水平、贫血指标水平、炎性因子水平及脂代谢水平，比较2组患者的临床疗效，并记录2组患者治疗期间药物不良反应的发生情况。结果 治疗后，2组患者的血清铁蛋白(serum ferritin，SF)、转铁蛋白(transferrin，TRF)、转铁蛋白饱和度(transferrin saturation，TSAT)、血细胞比容(hematocrit，Hct)、红细胞计数(red blood cell count，RBC)及血红白蛋白(hemoglobin，Hb)水平均显著提高，铁调素(hepcidin，Hepc)、C反应蛋白(C-reactive protein，CRP)、肿瘤坏死因子-α(tumor necrosis factor-α，TNF-α)、白细胞介素-6(interleukin-6，IL-6)、总胆固醇(total cholesterol，TC)及低密度脂蛋白(low density lipoprotein，LDL)水平均显著降低，且研究组的效果优于对照组(P<0。05);研究组的治疗总有效率(96。67%，58/60)高于对照组(78。33%，47/60)，P<0。05;治疗期间研究组不良反应发生率(3。33%)低于对照组(13。55%)，P<0。05。结论 罗沙司他联合琥珀酸亚铁可有效治疗MHD患者的肾性贫血，改善机体铁代谢水平及微炎症，且具有较高的安全性。
Comparison of the clinical efficacy of roxadustat and recombinant human erythropoietin combined with ferrous succinate in the treatment of renal anemia in hemodialysis patients
Objective To compare the clinical efficacy of roxadustat and recombinant human erythropoietin(rhEPO)combined with ferrous succinate in the treatment of renal anemia in maintenance hemodialysis(MHD)patients.Methods A total of 120 patients with MHD renal anemia were selected.According to the random number table method,the patients were divided into study group and control group,with 60 cases in each group.The control group was treated with rhEPO combined with ferrous succinate after dialysis,while the study group was treated with roxadustat combined with ferrous succinate after dialysis.Before and after treatment,the levels of iron metabolism,anemia index,inflammatory factor and lipid metabolism of the 2 groups were detected,the clinical efficacy were compared,and the adverse drug reactions were recorded.Results After treatment,the levels of serum ferritin(SF),transferrin(TRF),transferrin saturation(TSAT),hematocrit(Hct),red blood cell count(RBC),and hemoglobin(Hb)of the 2 groups were significantly increased,and the levels of hepcidin(Hepc),C-reactive protein(CRP),tumor necrosis factor-α(TNF-α),interleukin-6(IL-6)and total cholesterol(TC)and low density lipoprotein(LDL)were significantly reduced.The effect of the study group was better than that of the control group(P<0.05).The total effective rate of the study group was 96.67%(58/60),and the total effective rate of the control group was 78.33%(47/60),which was lower than that of the study group(P<0.05).During the treatment,the incidence of adverse reactions in the study group(3.33%)was lower than that in the control group(13.55%),P<0.05.Conclusion Roxadustat combined with ferrous succinate can effectively treat renal anemia in MHD patients,improve iron metabolism and microinflammation,and has good safety.
losartaniron succinaterecombinant human erythropoietin(rhEPO)maintenance hemodialysisrenal anemia
万方数据
维普
